The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology.
 
Henry Hiep Vo
No Relationships to Disclose
 
Siqing Fu
Research Funding - Abbisko (Inst); Anaeropharma (Inst); Arrien Pharmaceuticals (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Hookipa Pharma (Inst); Huya Bioscience International (Inst); IMV (Inst); Innovent Biologics (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); Medivir (Inst); Millennium (Inst); NCCN (Inst); NCCN (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NIH/NCI (Inst); Novartis (Inst); NovoCure (Inst); OncoMed (Inst); Parexel International, LLC (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); Taiho Oncology (Inst); Tolero Pharmaceuticals (Inst); Turnstone Bio (Inst)
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Presagia
Consulting or Advisory Role - Acuta; Adaptimmune; Alphasights; Amgen; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; COG; EcoR1 Capital; Genentech; Gerson Lehrman Group; GroupH; GroupH; Guidepoint Global; H.C. Wainwright & Co.; HCW Precision; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Janssen; Medscape; Merrimack; Numab; Pfizer; Prime Oncology; Seagen; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; WebMD; WebMD
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Aldai Norte (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Loxo; miRNA Therapeutics; Society for Immunotherapy of Cancer
 
Daniel D. Karp
No Relationships to Disclose
 
Sarina Anne Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; IDEAYA Biosciences; IFM Therapeutics; Immunomet; Jazz Pharmaceuticals; Novartis; PureTech; Sequenom; Sotio; Synlogic; Trovagene; Valeant/Dendreon
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Genentech (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Proximagen (Inst); Roche (Inst); Symphogen (Inst)
Other Relationship - Bio-Rad
 
Aung Naing
Consulting or Advisory Role - CSL Behring (I); CytomX Therapeutics; Horizon Pharma (I); Kymab; Novartis; OncoSec; STCube Pharmaceuticals Inc.; Takeda (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards; CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation; Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Surface Oncology; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences
 
Timothy A. Yap
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Axiom Biotechnologies; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; F-Star; Guidepoint Global; I-Mab; Ignyta; Janssen; Merck; Pfizer; Repare Therapeutics; Roche; Rubius Therapeutics; Schrodinger; Seagen; Varian Medical Systems; Zai Lab
Research Funding - Artios (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); ImmuneSensor Therapeutics (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tesaro (Inst); Vertex (Inst)
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Ellipses Pharma; Ionctura; Kelun; Lilly; Merck Sharp & Dohme; Molecular Partners; Novartis; NovellusDx; Orion; Peptomyc; Pfizer; Roche/Genentech; SERVIER; Spectrum Pharmaceuticals
Research Funding - Bayer; BioAtla; Blueprint Medicines; CytomX Therapeutics; Genmab; GlaxoSmithKline; Ipsen; Kelun; Novartis; Pfizer; Spectrum Pharmaceuticals; Symphogen; Takeda/Millennium; Tocagen
Travel, Accommodations, Expenses - Cancer Core Europe; Department of Defense; ESMO; Huntsman Cancer Institute; Karolinska Cancer Institute; King Abdullah International Medical Research Center; Louisiana State University; Molecular Partners
Other Relationship - Chinese University of Hong Kong; Elsevier; European Journal of Cancer; GlaxoSmithKline; SOLTI; Vall d'Hebron University Hospital Institute of Oncology
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Lilly; Merck; OncoTherics; zymeworks
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Carrie Cartwright
No Relationships to Disclose
 
Mohammad Faraz Naqvi
No Relationships to Disclose
 
Graciela M. Nogueras-Gonzalez
No Relationships to Disclose
 
Vincent A. Miller
Employment - EQRX; Foundation Medicine
Leadership - Revolution Medicines
Stock and Other Ownership Interests - EQRX; Foundation Medicine; Mirati Therapeutics; Revolution Medicines
Patents, Royalties, Other Intellectual Property - Receive periodic royalties related to T790M patent awarded to Memorial Sloan Kettering Cancer Center
 
Gary A. Palmer
Employment - Hope Oncology; Tempus
Leadership - Tempus
Stock and Other Ownership Interests - Tempus
 
David J Vining
Stock and Other Ownership Interests - Bracco Diagnostics; VisionSR
 
Donald A. Berry
Stock and Other Ownership Interests - Berry Consultants
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Mayo Clinic; Rutgers Cancer Institute of New Jersey
Consulting or Advisory Role - Aduro Biotech; Alkermes; Debiopharm Group; eFFECTOR Therapeutics; Genentech; IBM; Immunomedics; Inflection Biosciences; Jackson Laboratory for Genomic Medicine; Kolon Life Sciences; Mersana; Origimed; PACT Pharma; Parexel International; Pfizer; Puma Biotechnology; Roche; Samsung Bioepis; Seagen; Silverback Therapeutics; Spectrum Pharmaceuticals; Tyra Biosciences; Xencor; Zentalis; Zymeworks
Speakers' Bureau - Chugai Pharma
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (I); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jounce Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Beth Israel Deaconess Medical Center; Taiho Pharmaceutical
 
Apostolia Maria Tsimberidou
Consulting or Advisory Role - Tempus
Research Funding - Agenus (Inst); Boston Biomedical (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); OBI Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Placon (Inst); Stem Cells, Inc. (Inst); Tempus (Inst)
Travel, Accommodations, Expenses - Japanese Society of Clinical Oncology